Vaccines & Adjuvants

Aphios has demonstrated that its SuperFluids™ CFI pathogen inactivation technology has the capability for inactivating most viruses with negligible impact on protein integrity and antigenicity. Using SuperFluids™ CFI, the Company is developing a cost-effective HIV/AIDS vaccine. The Company is also developing a controlled release HIV/AIDS vaccine adjuvant utilizing its SuperFluids™ biodegradable polymer nanospheres technology.

• HIV/AIDS Vaccine -- The AIDS epidemic continues to spread, affecting millions of people worldwide. Only a safe and effective vaccine can arrest further rampage of this deadly disease. According to current consensus, a successful HIV vaccine will include a combination of several antigens and adjuvants to generate the broadest immune response possible. Aphios has demonstrated that SuperFluids™ CFI, with the capability for inactivating HIV, has negligible impact on protein integrity and antigenicity. Aphios is utilizing this technique for the creation of HIV/AIDS vaccines from genetically engineered HIV virions for a greater degree of safety and from combinations of different HIV strains for a broader degree of protection. The HIV vaccine manufacturing technology is cost-effective, amenable to large-scale processing and quite portable.

• HIV/AIDS Vaccine Adjuvant – Aphios is also developing a controlled release vehicle for HIV/AIDS vaccines by utilizing biodegradable polymeric nanospheres to protect and sustain the release of HIV viral antigens. This drug delivery vehicle will have the capability to deliver either whole inactivated HIV virions and/or HIV subunit vaccines. HIV antigens will be encapsulated by a nanoencapsulation technique that utilizes SuperFluids™. These fluids replace potentially harmful organic solvents, such as methylene chloride and ethyl acetate, eliminating the adverse effects of organic solvents to the potent but sensitive antigens, while reducing costs by eliminating unnecessary processing steps and improving the manufacturing environment.

Aphios’ vaccine and adjuvant manufacturing technologies will also find utility in the treatment of viral diseases such as influenza and others caused by emerging viral pathogens.

Home l Company | Product Pipeline | Patents | Press Releases | Purchase Products | Contact Aphios